Literature DB >> 6337503

Effect of intraportal and peripheral insulin on glucose turnover and recycling in diabetic dogs.

R W Stevenson, J A Parsons, K G Alberti.   

Abstract

The effects of peripheral and portal intravenous infusions of insulin on hepatic glucose production and glucose recycling have been compared in conscious diabetic dogs. Glucose turnover (Ra) was estimated using a priming dose of [3-3H]glucose and [1-14C]-glucose followed by constant intravenous infusion. Glucose recycling was calculated from 3H-Ra - 14C-Ra. In eight normal dogs, mean 3H-Ra was 3.0 mg X kg-1 X min-1 and recycling 19%. When these dogs were made diabetic with alloxan and streptozotocin the 3H-Ra rose to 6.2 mg X kg-1 X min-1 (P less than 0.001) and recycling to 24% (P less than 0.05). Insulin infusion for 2.5 h at 0.006 U X kg-1 X h-1 intraportally decreased 3H-Ra to 4.0 mg X kg-1 X min-1 (P less than 0.01 compared with untreated diabetic), whereas peripheral infusion at this rate had no significant effect. Insulin infusion at 0.05 U X kg-1 X h-1 by the peripheral and portal circulations reduced 3H-Ra to the normal range: 3.1 and 2.8 mg X kg-1 X min-1, respectively. Glucose recycling was also normalized by portal insulin infusion (20%) but was significantly decreased by peripheral infusion (11%, P less than 0.01). Thus the liver responds to lower infusion rates of insulin by the intraportal route, and only this mode of administration normalizes both hepatic glucose output and glucose recycling.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6337503     DOI: 10.1152/ajpendo.1983.244.2.E190

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  14 in total

Review 1.  Recent developments in insulin delivery techniques. Current status and future potential.

Authors:  F P Kennedy
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia.

Authors:  S D Mittelman; Y Y Fu; K Rebrin; G Steil; R N Bergman
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

Review 3.  The biochemistry of diabetes.

Authors:  R Taylor; L Agius
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

4.  Role of glucagon suppression on gluconeogenesis during insulin treatment of the conscious diabetic dog.

Authors:  R W Stevenson; P E Williams; A D Cherrington
Journal:  Diabetologia       Date:  1987-10       Impact factor: 10.122

5.  Increased glucose carbon recycling in severely insulin deficient type 1 (insulin-dependent) diabetic subjects.

Authors:  J J Benn; R Rai; P H Sönksen
Journal:  Diabetologia       Date:  1990-03       Impact factor: 10.122

6.  Hepatic glucose production during intraperitoneal and intravenous closed-loop insulin regulation of blood glucose in type 1 (insulin-dependent) diabetic patients.

Authors:  J J Robert; D Chauvet; D Darmaun; H Leblanc
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

7.  Free insulin levels and metabolic effects of meal-time bolus and square-wave intraperitoneal insulin infusion in insulin-dependent diabetic patients.

Authors:  J T Jimenez; S Walford; P D Home; I Hanning; K G Alberti
Journal:  Diabetologia       Date:  1985-10       Impact factor: 10.122

8.  Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs.

Authors:  A Giacca; S J Fisher; Z Q Shi; R Gupta; H L Lickley; M Vranic
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

9.  Comparison of portal and peripheral insulin delivery on carbohydrate metabolism in streptozotocin-diabetic rats.

Authors:  Y T Kruszynska; P D Home; K G Alberti
Journal:  Diabetologia       Date:  1985-03       Impact factor: 10.122

10.  Insulin resistance in alloxan-diabetic dogs: evidence for reversal following insulin therapy.

Authors:  G Caruso; J Proietto; A Calenti; F Alford
Journal:  Diabetologia       Date:  1983-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.